Corvus Pharmaceuticals, Inc. APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
Corvus Pharmaceuticals, Inc. (CRVS) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $12.00 thousand for the 12-month period ending 2019-12-31, per its 10-K filed 2022-03-10.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2022-03-10
- Corvus Pharmaceuticals, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2019-09-30 was $3.00K, a 57.14% decline year-over-year.
- Corvus Pharmaceuticals, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2019-06-30 was $4.00K, a 33.33% decline year-over-year.
- Corvus Pharmaceuticals, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2019-03-31 was $5.00K, a 28.57% decline year-over-year.
- Corvus Pharmaceuticals, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2018-09-30 was $7.00K.
- Corvus Pharmaceuticals, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2019 was $12.00K, a 57.14% decline from fiscal 2018.
- Corvus Pharmaceuticals, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2018 was $28.00K, a 0.00% change from fiscal 2017.
- Corvus Pharmaceuticals, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2017 was $28.00K, a 17.65% decline from fiscal 2016.
- Corvus Pharmaceuticals, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2016 was $34.00K.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2019-12-31 | $12.00K 10-K · filed 2022-03-10 | |||
| 2019-09-30 | $3.00K 10-Q · filed 2020-10-29 | $7.00K derived: sum of 2 quarters · filed 2020-10-29 | $12.00K derived: sum of 3 quarters · filed 2020-10-29 | |
| 2019-06-30 | $4.00K 10-Q · filed 2020-10-29 | $9.00K derived: sum of 2 quarters · filed 2020-10-29 | ||
| 2019-03-31 | $5.00K 10-Q · filed 2020-10-29 | |||
| 2018-12-31 | $28.00K 10-K · filed 2021-03-25 | |||
| 2018-09-30 | $7.00K 10-Q · filed 2019-10-29 | $13.00K derived: sum of 2 quarters · filed 2019-10-29 | $20.00K derived: sum of 3 quarters · filed 2019-10-29 | |
| 2018-06-30 | $6.00K 10-Q · filed 2019-10-29 | $13.00K derived: sum of 2 quarters · filed 2019-10-29 | ||
| 2018-03-31 | $7.00K 10-Q · filed 2019-10-29 | |||
| 2017-12-31 | $28.00K 10-K · filed 2020-03-09 | |||
| 2016-12-31 | $34.00K 10-K · filed 2019-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |